Outcomes in B non-Hodgkin lymphoma (B-NHL) patients undergonig autologous stem cell transplant (ASCT) in the Rituximab era: risk of hypogammaglobulinaemia and impact on post-ASCT infections

被引：0
|
作者：
Sola Soto, M. [1 ]
Serna Munoz, M. J. [1 ]
Munoz Ballester, J. [1 ]
Lopez Matencio, P. Iniesta [1 ]
Sanchez Blanco, J. J. [1 ]
Castilla Llorente, C. [1 ]
De Arriba de La Fuente, F. [1 ]
Garcia Malo, M. D. [1 ]
Perez Ceballos, E. [1 ]
Lopez Godino, O. [1 ]
Heras, I. [1 ]
Vicente Garcia, V. [1 ]
机构：
[1] Hosp Morales Meseguer, Hematol, Murcia, Spain
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P727
引用
收藏
页码：S502 / S503
页数：2
相关论文
共 50 条
  • [41] Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
    Ip, Andrew
    Switchenko, Jeffrey M.
    Graiser, Michael
    Koff, Jean Louise
    Gupta, Vikas Anand
    Lechowicz, Mary Jo
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Waller, Edmund K.
    Langston, Amelia A.
    Al-Kadhimi, Zaid S.
    Kota, Vamsi
    Blum, William G.
    Klisovic, Rebecca B.
    Blum, Kristie A.
    Hofmeister, Craig C.
    Allen, Pamela Blair
    Flowers, Christopher
    Cohen, Jonathon Brett
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL)
    Krishnan, Amrita
    Raubitschek, Andrew
    Nademanee, Auayporn P.
    Kogut, N.
    Popplewell, Leslie
    Tsai, Ni-Chun
    Palmer, Joycelynne
    Simpson, Jennifer
    Federico, Laura
    Yamauchi, Dave
    Forman, Stephen J.
    BLOOD, 2009, 114 (22) : 918 - 918
  • [43] Rituximab and Interleukin 2 (IL2) as treatment for CD20+non-Hodgkin's lymphoma (NHL) following autologous peripheral blood stem cell transplant (ASCT).
    Holmberg, LA
    Maloney, DG
    Bensinger, WI
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 566S - 566S
  • [44] Long term results of radioimmunotherapy with Bexxar/BEAM and autologous stem cell transplantation (ASCT) for chemotherapy resistant aggressive non-Hodgkin's lymphoma (NHL).
    Vose, JM
    Bierman, PJ
    Lynch, JC
    Bociek, GR
    Jacobs, C
    Armitage, JO
    BLOOD, 2003, 102 (11) : 248A - 248A
  • [45] Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma
    Tsirigotis, Panagiotis
    Dray, Liliane
    Resnick, Igor B.
    Ackerstein, Aliza
    Gesundheit, Benjamin
    Elad, Sharon
    Or, Reuven
    Shapira, Michael-Yechiel
    ANNALS OF HEMATOLOGY, 2010, 89 (03) : 263 - 272
  • [46] Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin’s lymphoma
    Panagiotis Tsirigotis
    Liliane Dray
    Igor B. Resnick
    Aliza Ackerstein
    Benjamin Gesundheit
    Sharon Elad
    Reuven Or
    Michael-Yechiel Shapira
    Annals of Hematology, 2010, 89 : 263 - 272
  • [47] Pharmacokinetic-Guided Therapeutic Dose Monitoring (TDM) of Busulfan Reduces Relapse of Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplantation (ASCT)
    Hill, Brian T.
    Rybicki, Lisa
    Urban, Theresa A.
    Lucerna, Mariana
    Jagadeesh, Deepa
    Gerds, Aaron T.
    Dean, Robert M.
    Sobecks, Ronald M.
    Pohlman, Brad
    Bolwell, Brian
    Kalaycio, Matt E.
    Hamilton, Betty K.
    Copelan, Edward A.
    Majhail, Navneet S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [48] Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)
    Wei, J. I. A.
    Xiao, Min
    Mao, Zekai
    Cao, Yang
    Xiao, Yi
    Meng, Fankai
    Zhang, Yicheng
    Zhou, Jianfeng
    Huang, Liang
    BLOOD, 2021, 138
  • [49] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
    Swinnen, L. J.
    Flinn, I. W.
    Kahl, B. S.
    Frey, E.
    Rogers, K.
    Jung, M.
    Jacene, H.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis
    Hua, Qingling
    Zhu, Yanzhe
    Liu, Hu
    JOURNAL OF CHEMOTHERAPY, 2015, 27 (06) : 365 - 370
12345